Skip to main content
. 2022 Jul 6;5:669. doi: 10.1038/s42003-022-03630-3

Fig. 2. Nanobodies for western blotting assays, ELISAs and lateral flow assays.

Fig. 2

a Nanobody-based western blotting assays of SARS-CoV-2 spikes: lysates of HEK293T cells expressing GFP or C-terminally C9-tagged SARS-CoV-2 spike (D614G) variants (indicated with numbers) were blotted with the indicated nanobodies. bd Sandwich ELISA: b signals of gradually diluted sample concentrations using P158 as the capture antibody and P86 or P543 (b, c) or P543-Fc (d) as the detection antibodies are graphed as a mean of the measurements from two technical replicates. In c, sequentially diluted lysates of HEK293T cells expressing the original SARS-CoV-2 spike (D614G) or Beta variant (D614G, N501Y, E484K and K417N) were assayed. Data are representative of one independent experiment out of two biologically independent experiments. e A photograph of the results from lateral flow nitrocellulose membrane assays: P158 for the capture line (allow head) and P86 for the detection beads; 300 ng of the purified SARS-CoV-2 spike Delta variant (D614G, L452R and T478K) (+) or PBS (–) was spotted.